Hepatic adverse drug reactions: A case/non-case study in Italy

European Journal of Clinical Pharmacology

Volumn 63, Issue 1, 2007, Pages 73-79

  Motola, Domenico ^a   Vargiu, Antonio ^a   Leone, Roberto ^b   Cocci, Alfredo ^c   Salvo, Francesco ^d   Ros, Barbara ^e   Meneghelli, Ilaria ^b   Venegoni, Mauro ^c   Cutroneo, Paola Maria ^d   Vaccheri, Alberto ^a   Velo, Gianpaolo ^b   Montanaro, Nicola ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c Lombardy Centre of Pharmacovigilance   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e Pharmaceutical Service   (Italy)

Author keywords

Adverse drug reactions; Liver toxicity; Spontaneous reporting

Indexed keywords

ACETIC ACID DERIVATIVE; ANTIANDROGEN; ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA1A INTERFERON; CERIVASTATIN; CYCLOOXYGENASE 2 INHIBITOR; DIAZEPINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID DERIVATIVE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDANTOIN DERIVATIVE; HYDRAZIDE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; SULFONAMIDE; TICLOPIDINE; TRIAZOLE DERIVATIVE; TRIMETHOPRIM; UNINDEXED DRUG;

ARTICLE; COMPARATIVE STUDY; DISEASE CLASSIFICATION; DRUG CLASSIFICATION; DRUG TOXICITY; HUMAN; ITALY; LIVER TOXICITY; NOMENCLATURE; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DATABASES, FACTUAL; DRUG MONITORING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IATROGENIC DISEASE; ITALY; LIVER DISEASES; MACROLIDES; PLATELET AGGREGATION INHIBITORS;

EID: 33845909019     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0222-z     Document Type: Article

References (37)

1. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200-1205
2. Larrey D (2000) Drug-induced liver diseases. J Hepatol 32:77-88
3. Lee WM (2003) Drug-induced hepatotoxicity. N Engl J Med 349:474-485
4. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, Hillon P (2002) Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36:451-455
5. WHO-Uppsala Monitoring center (2006) The use of the WHO-UMC system for standardised case causality assessment. WHO-Uppsala Monitoring Center
6. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11:3-10
7. Egberts AC, Meyboom RH, van Puijenbroek EP (2002) Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf 25:453-458
8. Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, Ollagnier M, Begaud B (1997) Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 44:513-518
9. WHO Collaborating Centre for International Drug Monitoring (2003) The WHO Adverse Reaction Terminology-Terminology for coding clinical information in relation to drug therapy. WHO Collaborating Centre for International Drug Monitoring
10. Leone R, Conforti A, Venegoni M, Motola D, Moretti U, Meneghelli I, Cocci A, Sangiorgi Cellini G, Scotto S, Montanaro N, Velo G (2005) Drug-induced anaphylaxis: case/non-case study based on an italian pharmacovigilance database. Drug Saf 28:547-556
11. van der Heijden PG, van Puijenbroek EP, van Buuren S, van der Hofstede JW (2002) On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Stat Med 21:2027-2044
12. Chalasani N (2005) Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 41:690-695
13. Chong PH, Seeger JD, Franklin C (2001) Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 111:390-400
14. de Denus S, Spinler SA, Miller K, Peterson AM (2004) Statins and liver toxicity: a meta-analysis. Pharmacotherapy 24:584-591
15. Rubenstein JH, Laine L (2004) Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 20:373-380
16. O'Connor N, Dargan PI, Jones AL (2003) Hepatocellular damage from non-steroidal anti-inflammatory drugs. Q J Med 96:787-791
17. Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M (2003) Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 327:18-22
18. Committee for Proprietary Medicinal Products. CPMP opinion following an article 31 referral-Nimesulide containing medicinal products-CPMP/1724/04. European Medicines Agency, London
19. Motola D, Vaccheri A, Silvani MC, Poluzzi E, Bottoni A, De Ponti F, Montanaro N (2004) Pattern of NSAID use in the Italian general population: a questionnaire-based survey. Eur J Clin Pharmacol 60:731-738
20. Carvajal Garcia-Pando A, Garcia OP, Rueda de Castro AM, Garcia DP (1999) Ticlopidine and hepatic adverse reactions. Data from the Spanish drug surveillance system. Med Clin (Barc) 112:557-558
21. Pizarro AE, Andrade RJ, Garcia-Cortes M, Lucena MI, Perez-Moreno JM, Puertas M, Sanchez-Martinez H, Montero JL, Duran JA, Jimenez M, Ruiz-Montero A, Soto-Conesa MJ, Rodrigo L, de Francisco R, Alcantara R, Camargo R (2001) Acute hepatitis due to ticlopidine. A report of 12 cases and review of the literature. Rev Neurol 33:1014-1020
22. Tremlett HL, Yoshida EM, Oger J (2004) Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology 62:628-631
23. Bravo AE, Drewe J, Schlienger RG, Krahenbuhl S, Pargger H, Ummenhofer W (2005) Hepatotoxicity during rapid intravenous loading with amiodarone: description of three cases and review of the literature. Crit Care Med 33:128-134
24. Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP, III, Banks PM (2006) Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 144:415-420
25. EMEA (2005) Ketek-summary of product characteristics. European Medicines Agency, London
26. Turner M, Corey GR, Abrutyn E (2006) Telithromycin. Ann Intern Med 144:447-448
27. Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V (2003) Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials 4:115-120
28. Kontorinis N, Dieterich DT (2003) Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 23:173-182
29. EMEA. Public Statement on Leflunomide (Arava)-Severe and serious hepatic reactions. EMEA/H/5611/01/n, European Medicines Agency, London, pp 1-6
30. van Roon EN, Jansen TL, Houtman NM, Spoelstra P, Brouwers JR (2004) Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf 27:345-352
31. James LP, Mayeux PR, Hinson JA (2003) Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 31:1499-1506
32. Chitturi S, George J (2002) Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 22:169-183
33. Larrey D, Vial T, Micaleff A, Babany G, Morichau-Beauchant M, Michel H, Benhamou JP (1992) Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut 33:368-371
34. Ersoz G, Karasu Z, Yildiz C, Akarca US, Yuce G, Batur Y (2001) Severe toxic hepatitis associated with amoxycillin and clavulanic acid. J Clin Pharm Ther 26:225-229
35. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, Garcia-Munoz B, Gonzalez-Grande R, Pizarro A, Duran JA, Jimenez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmeron J, Martin-Vivaldi R, Spanish Group for the Study of Drug-Induced Liver Disease (2005) Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129:512-521
36. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247-1255
37. Maddrey WC, Maurath CJ, Verburg KM, Geis GS (2000) The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. Am J Ther 7:153-158